DR15-DQ6 在生命前五十年对1型糖尿病保持显性保护作用
在ADDRESS-2队列(n=1458)和UK Biobank(n=2502)两个独立队列中,评估白人欧洲血统1型糖尿病患者携带DR15-DQ6的比例及其相对于人群对照的保护作用。结果显示DR15-DQ6在0-50岁各发病年龄组均具保护性(OR均<1,均p<0.001),ADDRESS-2中5-18岁OR 0.16(95%CI 0.08,0.31)、19-30岁OR 0.10(0.04,0.23)、31-50岁OR 0.37(0.21,0.68),UK Biobank中各年龄段亦保持高度保护。
要点
- DR15-DQ6对1型糖尿病的保护作用贯穿生命前50年。
- ADDRESS-2中31-50岁发病者OR 0.37(95%CI 0.21,0.68)。
- 缺乏DR15-DQ6时,DR3-DQ2或DR4-DQ8增加1型糖尿病风险。
核心结论
- HLA DR15-DQ6在整个生命前五十年对1型糖尿病具有显性保护作用。
研究设计与样本
- 在ADDRESS-2队列(n=1458,经胰岛自身抗体确诊的临床诊断1型糖尿病)和UK Biobank(n=2502)两个独立队列中评估DR15-DQ6携带比例并与人群对照比较。
- 分析限于白人欧洲血统,按1型糖尿病发病年龄分为0-18岁、19-30岁和31-50岁三组。
- UK Biobank中使用泊松回归按HLA分组估计相对于基线HLA风险的1型糖尿病发病率。
主要发现
- DR15-DQ6对1型糖尿病的保护作用持续至50岁(各年龄组OR<1,均p<0.001)。
- ADDRESS-2中相对中性HLA基因型的1型糖尿病OR:5-18岁OR 0.16(95%CI 0.08,0.31);19-30岁OR 0.10(0.04,0.23);31-50岁OR 0.37(0.21,0.68)。
- UK Biobank中DR15-DQ6在所有年龄组均保持高度保护。
- 无DR15-DQ6时,携带主要1型糖尿病高风险单倍型(DR3-DQ2或DR4-DQ8)与1型糖尿病风险增加相关。
关键数值与推荐
- ADDRESS-2中5-18岁发病者DR15-DQ6的1型糖尿病OR 0.16(95%CI 0.08,0.31)。
- ADDRESS-2中19-30岁发病者OR 0.10(95%CI 0.04,0.23)。
- ADDRESS-2中31-50岁发病者OR 0.37(95%CI 0.21,0.68)。
临床怎么用
- 在临床遗传风险评估中,DR15-DQ6可视为贯穿成年期的1型糖尿病保护性标志。
- 对于携带DR3-DQ2或DR4-DQ8且无DR15-DQ6者,应关注1型糖尿病风险增加。
局限性
- 分析仅限白人欧洲血统人群。
- ADDRESS-2中1型糖尿病经胰岛自身抗体确诊,UK Biobank中采用泊松回归估计发病率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Among white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased. METHODS: In two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0-18 years, 19-30 years and 31-50 years. RESULTS: DR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, all p < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5-18 years OR 0.16 (95% CI 0.08, 0.31); age 19-30 years OR 0.10 (0.04, 0.23); and age 31-50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes. CONCLUSIONS/INTERPRETATION: HLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life.
引用
- Thomas NJ, Dennis JM, Sharp SA, et al. DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life. Diabetologia. 2021. PMID: 34272580. doi:10.1007/s00125-021-05513-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。